[1. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012 Aug;13(8):790-801. DOI: 10.1016/S1470-2045(12)70211-510.1016/S1470-2045(12)70211-5]Search in Google Scholar
[2. Reports based on the data the Oncology Centre: http://85.128.14.124/krn/, www.onkologia.org. Access: 10.12.2017 05.04.2017.10.1055/s-0043-100246]Search in Google Scholar
[3. Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Kjaerbye-Thygesen A, Gayther S, et al. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish “MALOVA” Ovarian Cancer Study. Gynecol Oncol. 2007 Mar;104(3):508-15. DOI: 10.1016/j.ygyno. 2006.09.028]Search in Google Scholar
[4. Scharl A, Crombach G, Vierbuchen M, Müsch H, Bolte A. CA 125 in normal tissues and carcinomas of the uterine cervix, endometrium and fallopian tube. I. Immunohistochemical detection. Arch Gynecol Obstet. 1989 Jun;244(2):103-12. DOI: 10.1007/BF0093138110.1007/BF00931381]Search in Google Scholar
[5. Sadowski EA, Robbins JB, Guite K, Patel-Lippmann K, Del Rio AM, Kushner DM, et al. Preoperative pelvic MRI and serum cancer antigen-125: selecting women with grade 1 endometrial cancer for lymphadenectomy. AJR Am J Roentgenol. 2015 Nov;205(5):W556-64. DOI: 10.2214/AJR.14.1374610.2214/AJR.14.13746]Search in Google Scholar
[6. Rizzuto I, Stavraka C, Chatteriee J, Borley J, Hopkins TG, Gabra H, et al. Risk of Ovarian Cancer Relapse Score: a prognostic algorithm to predict relapse following treatment for advanced ovarian cancer. Int J Gynecol Cancer. 2015 Mar;25(3):416-22. DOI: 10.1097/IGC.000000000000036110.1097/IGC.0000000000000361]Search in Google Scholar
[7. Tsai CC, Liu YS, Huang EY, Huang SC, Chang HW, Tseng CW, ChangChien CC et al. Value of preoperative serum CA125 in early-stage adenocarcinoma of the uterine cervix without pelvic lymph node metastasis. Gynecol Oncol. 2006 Mar;100(3):591-5. DOI: 10.1016/j.ygyno.2005.09.04910.1016/j.ygyno.2005.09.049]Search in Google Scholar
[8. Gadducci A, Tana R, Cosio S, Genazzani AR. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol. 2008 Apr;66(1):10-20. DOI: 10.1016/j. critrevonc.2007.09.002]Search in Google Scholar
[9. Porika M, Vemunoori AK, Tippani R, Mohammad A, Bollam SR, Abbagani S. Squamous cell carcinoma antigen and cancer antigen 125 in southern Indian cervical cancer patients. Asian Pac J Cancer Prev. 2010 Jun;11(6):1745-7.]Search in Google Scholar
[10. Takeda M, Sakuragi N, Okamoto K, Todo Y, Minobe S, Nomura E, et al. Preoperative serum SCC, CA125, and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix. Acta Obstet Gynecol Scand. 2002 May;81(5):451-7. DOI: 10.1034/j.1600-0412.2002.810513.x10.1034/j.1600-0412.2002.810513.x]Search in Google Scholar
[11. Koper NP, Thomas CM, Dorn KE, Schijf CP. Improvement of clinical staging in cervical cancer with serum squamous cell carcinoma antigen and CA 125 determinations. Gynecol Oncol. 1997 Mar;64(3):473-6. DOI: 10.1006/gyno.1996.458110.1006/gyno.1996.4581]Search in Google Scholar
[12. Avall-Lundqvist EH, Sjövall K, Nilsson BR, Eneroth PH. Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and CA 125 in cervical carcinoma. Eur J Cancer. 1992;28A(10):1695-702. DOI: 10.1016/0959-8049(92)90071-910.1016/0959-8049(92)90071-9]Search in Google Scholar
[13. Davelaar EM, van de Lande J, von Mensdorff-Pouilly S, Blankenstein MA, Verheijen RH, Kenemans P. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer. Tumour Biol. 2008;29(1):9-17. DOI: 10.1159/00013256610.1159/00013256618497544]Search in Google Scholar
[14. Ueda Y, Enomoto T, Kimura T, Miyatake T, Yoshiho K, Fujita M, et al. Serum biomarkers for early detection of gynecologic cancers. Cancers (Basel). 2010 Jun 14;2(2):1312-27. DOI: 10.3390/cancers202131210.3390/cancers2021312383513124281117]Search in Google Scholar
[15. Bats A, Mathevet P, Buenerd A, Orliaquet I, Mery E, Zerdoud S, et al. The sentinel node technique detects unexpected drainage pathways and allows nodal ultrastaging in early cervical cancer: insights from the multicenter prospective SENTICOL study. Ann Surg Oncol. 2013 Feb;20(2):413-22. DOI: 10.1245/s10434-012-2597-710.1245/s10434-012-2597-722911367]Search in Google Scholar
[16. Borras G, Molina R, Xercevanis J, Ballesta A, Iglesias J. Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix. Gynecol Oncol. 1995 May;57(2):205-11. DOI: 10.1006/gyno.1995.112610.1006/gyno.1995.11267729735]Search in Google Scholar
[17. Kotowicz B, Kaminska J, Fuksiewicz M, Kowalska M, Jonska-Gmyrek J, Gawrychowski K, et al. Clinical significance of serum CA-125 and soluble tumor necrosis factor receptor type I in cervical adenocarcinoma patients. Int J Gynecol Cancer. 2010 May;20(4):588-92. DOI: 10.1111/IGC.0b013e3181d5c27a10.1111/IGC.0b013e3181d5c27a20686378]Search in Google Scholar
[18. Yamazaki H, Todo Y, Okamoto K, Yamashiro K, Kato H. Pretreatment risk factors for parametrial involvement in FIGO stage IB1 cervical cancer. J Gynecol Oncol. 2015 Oct;26(4):255-61. DOI: 10.3802/jgo.2015.26.4.25510.3802/jgo.2015.26.4.255462036126197769]Search in Google Scholar
[19. Darai E, Rouzier R, Ballester M, Barranger E, Coutant C. Sentinel lymph node biopsy in gynaecological cancers: the importance of micrometastases in cervical cancer. Surg Oncol. 2008 Sep;17(3):227-35. DOI: 10.1016/j.suronc.2008.04.00210.1016/j.suronc.2008.04.00218504122]Search in Google Scholar
[20. Slama J, Dundr P, Dusek L, Fischerova D, Pinakavova I, Vrzackova P, et al. Sentinel lymph node status in patients with locally advanced cervical cancers and impact on neoadjuvant chemotherapy. Gynecol Oncol. 2012 May;125(2):303-6. DOI: 10.1016/j.ygyno.2012.02.01010.1016/j.ygyno.2012.02.01022342976]Search in Google Scholar
[21. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009 May;105(2):103-4. DOI: 10.1016/j. ijgo.2009.02.009 DOI: 10.1016/j.ijgo.2009.02.012 ]Search in Google Scholar
[22. Schwartz GF, Giuliano AE, Veronesi U. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast. April 15-22, 2001. Philadelphia. Pennsylvania. Cancer. 2002 May 15;94(10):2542-51. DOI: 10.1002/cncr.1053910.1002/cncr.1053912173319]Search in Google Scholar
[23. Singletary SE, Greene FL. Revision of breast cancer staging: the 6th edition of the TNM Classification. Semin Surg Oncol. 2003 Nov;21(1):53-9. DOI: 10.1002/ssu.1002110.1002/ssu.1002112923916]Search in Google Scholar
[24. Goldberg GL, Sklar A, O’Hanlan KA, Levine PA, Runowicz CD. CA-125: a potential prognostic indicator in patients with cervical cancer? Gynecol Oncol. 1991 Mar;40(3):222-4. DOI: 10.1016/0090-8258(90)90281- O]Search in Google Scholar
[25. Divine LM, Kizer NT, Hagemann AR, Pittman ME, Chen L, Powell MA, et al. Clinicopathologic characteristics and survival of patients with gynecologic malignancies metastatic to the brain. Gynecol Oncol. 2016 Jul;142(1):76-82. DOI: 10.1016/j.ygyno.2016.04.03010.1016/j.ygyno.2016.04.030509638827117923]Search in Google Scholar
[26. Dasari S, Wudayagiri R, Valluru L. Cervical cancer: biomarkers for diagnosis and treatment. Clin Chim Acta. 2015 May 20;445:7-11. DOI: 10.1016/j. cca.2015.03.005]Search in Google Scholar
[27. Rimel BJ, Burke WM, Higgins RV, Lee PS, Lutman CV, Parker L. Improving quality and decreasing cost in gynecologic oncology care. Society of gynecologic oncology recommendations for clinical practice. Gynecol Oncol. 2015 May;137(2):280-4. DOI: 10.1016/j.ygyno. 2015.02.021]Search in Google Scholar
[28. Hoogendam JP, Zaal A, Rutten EG, Heijnen CJ, Kenter GG, Veldhuis WB, et al. Detection of cervical cancer recurrence during follow-up: a multivariable comparison of 9 frequently investigated serum biomarkers. Gynecol Oncol. 2013 Dec;131(3):655-60. DOI: 10.1016/j.ygyno.2013.10.01610.1016/j.ygyno.2013.10.01624157617]Search in Google Scholar
[29. Kupets R, Giede KC, Power P, Agrawal A; Executive of the Society Gynecologic Oncology of Canada. The investigations required before referring a patient to a gynecologic oncologist. J Obstet Gynaecol Can. 2016 Feb;38(2):164-7. DOI: 10.1016/j.jogc.2015.12.01610.1016/j.jogc.2015.12.01627032742]Search in Google Scholar
[30. Togami S, Sasajima Y, Kasamatsu T, Oda-Otomo R, Okada S, Ishikawa M, et al. Immunophenotype and human papillomavirus status of serous adenocarcinoma of the uterine cervix. Pathol Oncol Res. 2015 Apr;21(2):487-94. DOI: 10.1007/s12253-014-9854-y 10.1007/s12253-014-9854-y25370301]Search in Google Scholar